Response of Multiple Recurrent TaT1 Bladder Cancer to Intravesical Apaziquone (EO9): Comparative Analysis of Tumor Recurrence Rates

A Prospective European Organization for Research and Treatment of Cancer Genitourinary Group Randomized Trial Comparing Transurethral Resection Followed by a Single Intravesical Instillation of Epirubicin or Water in Single Stage Ta, T1 Papillary Carcinoma of the Bladder

Willem Oosterlinck, Karl H. Kurth, Fritz H. Schröder et al. · The Journal of Urology · 1993 · 366 citations

Enzyme-directed bioreductive drug development revisited: a commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase.

Paul Workman · PubMed · 1994 · 124 citations

Medicinal Chemistry, Biosynthesis, Bioorganic Chemistry +15

Effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: interim report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party)

David A. Tolley, T. B. Hargreave, Philip H. Smith et al. · BMJ · 1988 · 104 citations · Full text

Control Group, Urology, Surgical Oncology +13

EO9: A novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models

Hans R. Hendriks, P. E. Pizao, Dan Berger et al. · European Journal of Cancer · 1993 · 104 citations

Tumor Biology, Preclinical Models, Medicine +7

Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours

BP Cronin · British Journal of Cancer · 1998 · 78 citations

Drug Targeting, Preclinical Drug Evaluation, Medicine +10